Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos

Blood (2019) 134 (Supplement_1): 694.

https://doi.org/10.1182/blood-2019-123997

Published: 2019

Journal Articles

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Smith Giri, MBBS, Peter Barth, MD, Luciano J. Costa, MD PhD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 1862.

https://doi.org/10.1182/blood-2019-131231

Published: 2019

Journal Articles

Incidence of Second Primary Malignancies and Association with Treatment in US Veterans with Multiple Myeloma

Nathanael Fillmore, PhD, Sarvari Venkata Yellapragada, MD, Cenk Yildirim, MS, Aimaz Afrough, MD, Adanma Anji Ayanambakkam Attanathi, MD, Ifeorah Chizoba, MPH, Nhan Do, MD, Mary Brophy, MD MPH, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 1806.

https://doi.org/10.1182/blood-2019-132227

Published: 2019

Journal Articles

Risk of Second Primary Malignancy in Multiple Myeloma in the Novel Therapy Era from 15 Years of Cancer Registry

Hsin-An Hou, Yanfang Liu, MD MPH, Hong Qiu, MD PhD, Hwei-Fang Tien, MD, PhD, Chao-Hsiun Tang

Blood (2019) 134 (Supplement_1): 1878.

https://doi.org/10.1182/blood-2019-124296

Published: 2019

Journal Articles

Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study

Donna E Reece, MD, Giovanni Piza Rodriguez, MD, Mariela A Pantoja, PhD MSc, Darrell J White, MD, Christopher P Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Martha L Louzada, MDMSc, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger E Tiedemann, MBChB, PhD, Harminder K Paul, MSc, Christine I Chen, MD

Blood (2019) 134 (Supplement_1): 4570.

https://doi.org/10.1182/blood-2019-129357

Published: 2019

Journal Articles

Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen

Thura Win Htut, MBBS, MRCP, Donald P. Quick, MD, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Somedeb Ball, MD, Ei Moe Phyu, MD, Nyein Htway Yu, MBBS, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Nicholas D'Cunha, MD, Sanjay Awasthi, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5550.

https://doi.org/10.1182/blood-2019-123156

Published: 2019

Journal Articles

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

Kalyan Nadiminti, Abhishek A Mangaonkar, MBBS, Kimberly J. Langer, D.N.P., C.N.P., Shakila P Khan, MD, Vilmarie Rodriguez, MD, Naseema Gangat, MBBS, Michelle A Elliott, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mark Litzow, MD, William J Hogan, MB, BCh, Saad S. Kenderian, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 3300.

https://doi.org/10.1182/blood-2019-121742

Published: 2019

Journal Articles

Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance

John R Jones, MD, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, Rachel Sigsworth, Matthew Jenner, MBBS, MRCP, FRCPath, Martin F. Kaiser, Rebecca Mottram, BA, BSc, Mark T Drayson, MB ChB, PhD FRCPath, Gordon Cook, Walter M Gregory, PhD, Roger G. Owen, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 3132.

https://doi.org/10.1182/blood-2019-127469

Published: 2019

Journal Articles

Resolvin D4 attenuates the severity of pathological thrombosis in mice

Deya Cherpokova, Charlotte C. Jouvene, Stephania Libreros, Elise P. DeRoo, Long Chu, Xavier de la Rosa, Paul C. Norris, Denisa D. Wagner, Charles N. Serhan

Blood (2019) 134 (17): 1458–1468.

https://doi.org/10.1182/blood.2018886317

Published: 2019

Includes: Supplemental data

Journal Articles

Risk of Second Primary Malignancies in Chronic Lymphocytic Leukemia

Anuhya Kommalapati, MD, Sri Harsha Tella, MD, Gaurav Goyal, MBBS

Blood (2018) 132 (Supplement 1): 3581.

https://doi.org/10.1182/blood-2018-99-120123

Published: 2018

Journal Articles

Tumor Associated Macrophages (TAM) Antagonize Chimeric Antigen Receptor (CAR) T Cell Therapy in Peritoneal Solid Tumors and Are Reprogrammed to Fight the Tumor By Therapeutic Apoptotic Cells

Netanel Karbian, PhD, Raja Amore, MsC, Dror Mevorach, MD

Blood (2018) 132 (Supplement 1): 5377.

https://doi.org/10.1182/blood-2018-99-120280

Published: 2018

Journal Articles

Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL)

Vivek Kumar, MD, M.B.,B.S., Sikander Ailawadhi, Leyla Bojanini, MD, Aditya Mehta, Anshika Singh, Taimur Sher, MD, Vivek Roy, MD, Prakash Vishnu, MD, Julian A Marin-Acevedo, Victoria R. Alegria, Aneel Paulus, MD, Sonikpreet Aulakh, MD, Madiha Iqbal, MBBS, Rami Manochakian, MD, Winston Tan, MD, Asher A. Chanan-Khan, MD, Meghna Ailawadhi, MD

Blood (2018) 132 (Supplement 1): 4869.

https://doi.org/10.1182/blood-2018-99-116361

Published: 2018

Journal Articles

Expression of Recombinant β2GPI and Site-Directed Mutants Provides Insight into the Pathogenesis of Antiphospholipid Syndrome

Ravi Kumar Alluri, PhD, Suman Kundu, MBA, Jack Su, PhD, Sekhar Kambakam, Edward Yu, PhD, Keith R. McCrae, MD

Blood (2018) 132 (Supplement 1): 1226.

https://doi.org/10.1182/blood-2018-99-117665

Published: 2018

Journal Articles

Second Primary Malignancies in Peripheral T-Cell Lymphoma, Not Otherwise Specified; A SEER Database Analysis

Ranju Kunwor, MD, Mahesh Nepal, MD, Dominic Ho, MD PhD, Krishna Ghimire, MD

Blood (2018) 132 (Supplement 1): 5923.

https://doi.org/10.1182/blood-2018-99-120194

Published: 2018

Journal Articles

Changes in Second Primary Malignancies (SPM) after Hodgkin Lymphoma over Time in the United States

Amy Steele, BS, Qian Li, MS, Ann M Brunson, MS, Aaron S. Rosenberg, MD, Ted Wun, MD FACP, FRCPA, Theresa H.M. Keegan, PhD MS

Blood (2017) 130 (Supplement 1): 4097.

https://doi.org/10.1182/blood.V130.Suppl_1.4097.4097

Published: 2017

Journal Articles

Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial

Blood (2017) 130 (Supplement 1): 4328.

https://doi.org/10.1182/blood.V130.Suppl_1.4328.4328

Published: 2017

Journal Articles

Second Primary Malignancies in Patients with Non-Hodgkin Lymphoma

Yucai Wang, MD, Yanru Wang, MD PhD, Gita Thanarajasingam, MD, Carrie A Thompson, MD, Thomas M Habermann, MD, Grzegorz S Nowakowski, MD, Michael Wang, BS

Blood (2017) 130 (Supplement 1): 2152.

https://doi.org/10.1182/blood.V130.Suppl_1.2152.2152

Published: 2017

Journal Articles

Prognostic Impact of Past History of Other Malignancies in Diffuse Large B Cell Lymphoma

Kazuna Tanba, MD, Yoshiaki Chinen, MDPhD, Hitoji Uchiyama, MD PhD, Nobuhiko Uoshima, MD PhD, Kazuho Shimura, MD PhD, Shin-ichi Fuchida, MD PhD, Miki Kiyota, MD PhD, Mitsushige Nakao, MD PhD, Yuji Shimura, MD PhD, Tsutomu Kobayashi, MD PhD, Shigeo Horiike, MD PhD, Katsuya Wada, MD PhD, Chihiro Shimazaki, MD PhD, Hiroto Kaneko, MD PhD, Yutaka Kobayashi, MD PhD, Masafumi Taniwaki, MD PhD, Junya Kuroda, MD PhD

Blood (2017) 130 (Supplement 1): 1570.

https://doi.org/10.1182/blood.V130.Suppl_1.1570.1570

Published: 2017

Journal Articles

Influential Role of Macrophages in Hepcidin Regulation in Apo-Transferrin Treated β-Thalassemic Mice

Daniel Moskop, Shuming Sun, PhD, Maria Feola, PhD, Marc Ruiz Martinez, PhD, Huiyong Chen, PhD, Jing Liu, PhD, Nathan Brinkman, PhD, Robert E Fleming, MD, Stefano Rivella, PhD, Yelena Ginzburg, MD

Blood (2017) 130 (Supplement 1): 172.

https://doi.org/10.1182/blood.V130.Suppl_1.172.172

Published: 2017

NARROW

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Incidence of Second Primary Malignancies and Association with Treatment in US Veterans with Multiple Myeloma

Risk of Second Primary Malignancy in Multiple Myeloma in the Novel Therapy Era from 15 Years of Cancer Registry

Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study

Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance

Resolvin D4 attenuates the severity of pathological thrombosis in mice

Risk of Second Primary Malignancies in Chronic Lymphocytic Leukemia

Tumor Associated Macrophages (TAM) Antagonize Chimeric Antigen Receptor (CAR) T Cell Therapy in Peritoneal Solid Tumors and Are Reprogrammed to Fight the Tumor By Therapeutic Apoptotic Cells

Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL)

Expression of Recombinant β2GPI and Site-Directed Mutants Provides Insight into the Pathogenesis of Antiphospholipid Syndrome

Second Primary Malignancies in Peripheral T-Cell Lymphoma, Not Otherwise Specified; A SEER Database Analysis

Changes in Second Primary Malignancies (SPM) after Hodgkin Lymphoma over Time in the United States

Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial

Second Primary Malignancies in Patients with Non-Hodgkin Lymphoma

Prognostic Impact of Past History of Other Malignancies in Diffuse Large B Cell Lymphoma

Influential Role of Macrophages in Hepcidin Regulation in Apo-Transferrin Treated β-Thalassemic Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only